These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18690954)

  • 41. Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy.
    Nsimba SE
    East Afr J Public Health; 2008 Dec; 5(3):205-10. PubMed ID: 19374325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Off-label and unlicensed drug use among neonatal intensive care units in Southern Italy.
    Laforgia N; Nuccio MM; Schettini F; Dell'Aera M; Gasbarro AR; Dell'Erba A; Solarino B
    Pediatr Int; 2014 Feb; 56(1):57-9. PubMed ID: 23937449
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe.
    Minghetti P; Pantano D; Gennari CG; Casiraghi A
    Health Policy; 2014 Sep; 117(3):328-33. PubMed ID: 25110297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preparation of medicines for children - a hierarchy of classification.
    Ernest TB; Craig J; Nunn A; Salunke S; Tuleu C; Breitkreutz J; Alex R; Hempenstall J
    Int J Pharm; 2012 Oct; 435(2):124-30. PubMed ID: 22677416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Drug Content, Stability Analysis, and Qualitative Assessment of Pharmacists' Opinions of Two Exemplar Extemporaneous Formulations.
    Kirkby M; Moffatt K; Rogers AM; McCague PJ; McElnay JC; Quinn C; McCullough LA; Barry J; Donnelly RF
    Molecules; 2020 Jul; 25(13):. PubMed ID: 32640709
    [TBL] [Abstract][Full Text] [Related]  

  • 46. WHO expert committee on specifications for pharmaceutical preparations. Fortieth report.
    WHO Expert Committee on Specifications for Pharmaceutical Preparations
    World Health Organ Tech Rep Ser; 2006; 937():1-461, back cover. PubMed ID: 16836287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
    Conroy S
    Acta Paediatr; 2003 Apr; 92(4):408-10. PubMed ID: 12801103
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prescription of compounded ophthalmic medications-a pharmacy perspective.
    Weekes L; Ramzan I
    Clin Exp Optom; 2021 Apr; 104(3):406-411. PubMed ID: 32253769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development and content validation of an assessment tool for medicine compounding on hospital wards.
    Suvikas-Peltonen E; Granfors E; Celikkayalar E; Laaksonen R; Palmgren J; Airaksinen M
    Int J Clin Pharm; 2016 Dec; 38(6):1457-1463. PubMed ID: 27817169
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Challenges in pediatric drug use: A pharmacist point of view.
    Balan S; Hassali MA; Mak VSL
    Res Social Adm Pharm; 2017; 13(3):653-655. PubMed ID: 27493130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Basics of Sterile Compounding: Vehicles Used in Sterile Compounding.
    Allen LV
    Int J Pharm Compd; 2019; 23(3):221-228. PubMed ID: 31085791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
    Humfrey CD
    Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Off-label prescription of genetically modified organism medicines in europe: emerging conflicts of interest?
    Schagen FH; Hoeben RC; Hospers GA
    Hum Gene Ther; 2014 Oct; 25(10):893-6. PubMed ID: 25268158
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases.
    Vanhoorne V; Peeters E; Van Tongelen I; Boussery K; Wynendaele E; De Spiegeleer B; Remon JP; Vervaet C
    Orphanet J Rare Dis; 2019 Aug; 14(1):186. PubMed ID: 31370862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Off-label and unlicensed drug use: Results from a pilot study in a pediatric intensive care unit].
    García-López I; Fuentes-Ríos JE; Manrique-Rodríguez S; M Fernández-Llamazares C
    An Pediatr (Barc); 2017 Jan; 86(1):28-36. PubMed ID: 27151379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Off-label and unlicensed utilisation of medicines in a French paediatric hospital.
    Joret-Descout P; Prot-Labarthe S; Brion F; Bataille J; Hartmann JF; Bourdon O
    Int J Clin Pharm; 2015 Dec; 37(6):1222-7. PubMed ID: 26394784
    [TBL] [Abstract][Full Text] [Related]  

  • 57. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2012; (970):1-235, back cover. PubMed ID: 22894011
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Council of Europe Resolution CM/Res(2016)2: a major contribution to patient safety from reconstituted injectable medicines?
    Beaney AM; Le Brun P; Ravera S; Scheepers H
    Eur J Hosp Pharm; 2020 Jul; 27(4):216-221. PubMed ID: 32587080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interventions of hospital pharmacists in improving drug therapy in children: a systematic literature review.
    Sanghera N; Chan PY; Khaki ZF; Planner C; Lee KK; Cranswick NE; Wong IC
    Drug Saf; 2006; 29(11):1031-47. PubMed ID: 17061909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites.
    Juhlin K; Karimi G; Andér M; Camilli S; Dheda M; Har TS; Isahak R; Lee SJ; Vaughan S; Caduff P; Norén GN
    Drug Saf; 2015 Apr; 38(4):373-82. PubMed ID: 25687792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.